News

Committed to Innovation: Roanoke Blacksburg Innovation Alliance Replaces Verge

The Roanoke Blacksburg Innovation Alliance, formerly Verge, unveiled a major rebrand to reflect their ongoing commitment to tech-based economic advancement and their leadership in a portfolio of organizations dedicated to developing the Roanoke Blacksburg innovation ecosystem.

The elements of the Roanoke Blacksburg Innovation Alliance (RBIA) include:

  • A new name that reflects the commitment of Roanoke Blacksburg Innovation Alliance to elevating the local tech economy through vision, strategy, and collaboration.
  • A dynamic and modern logo that represents all four Alliance teams and evokes the momentum and creativity inherent in the regional innovation ecosystem.
  • Energetic brand colors that align across RBIA member companies.
  • A modern, user-friendly website designed to support existing innovation ecosystem members and attract new stakeholders.
“The new brand visually embodies the interconnected efforts of the Alliance and our collective vision to elevate the Roanoke Region and New River Valley as a nationally recognized hub for technology and biotechnology,” said RBIA CEO Erin Burcham.
The Alliance has accelerated 60+ tech companies and seen 850 high-paying jobs created in the region since 2017 and has been instrumental in crafting a creative culture that has seen 3,200+ patents filed since 2014. Further, through RBTC, the Alliance brings together 225 RBTC member companies for professional development, networking and talent retention.

Most recently, RBIA led a coalition to include 38 regional organizations, including Virginia Tech, Carilion, Virginia Western Community College, Blue Ridge Partnership for Health Science Careers and many others, to secure $4.9 million through GO Virginia’s Project VITAL. The funds will be used to further biotech and life science commercialization and establish Roanoke Blacksburg as a biomedical hub. The coalition aims to create 1,100 jobs over five years with a $40 million economic impact.

Roanoke Blacksburg Innovation Alliance unites a portfolio of organizations including Regional Accelerator and Mentoring Program (RAMP), Roanoke Blacksburg Technology Council (RBTC), and Common Wealth Angels all dedicated to tech-based economic advancement in the Roanoke Blacksburg region. Together, they form a full-stack network of support designed to accelerate innovation in the technology and life science industries and develop the Roanoke Blacksburg region into a nationally recognized hub for technology and biotechnology.

“The rebrand of the Roanoke Blacksburg Innovation Alliance honors the dedication of past leaders and the contributions of many collaborators in building a strong foundation for innovation in our region. It also sets a bold vision for the ambitious goals we will achieve together in the future,” Burcham said.

To experience the new look of Roanoke Blacksburg Innovation Alliance, visit rbia.tech.

Recent News

03/18/2025

Committed to Innovation: Roanoke Blacksburg Innovation Alliance Replaces Verge

The Roanoke Blacksburg Innovation Alliance, formerly Verge, unveiled a major rebrand to reflect their ongoing commitment to tech-based economic advancement and their leadership in a portfolio of organizations dedicated to developing the Roanoke Blacksburg innovation ecosystem. The elements of the Roanoke Blacksburg Innovation Alliance (RBIA) include: A new name that reflects the commitment of Roanoke Blacksburg

03/14/2025

CEL-SCI’s Head and Neck Cancer Study Clears FDA Review, Eyes Commercialization Partners

CEL-SCI Corporation announced that a third-party study published on March 6, 2025 in JAMA Oncology titled “Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial” provided data that support Multikine’s use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression

03/13/2025

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This investment underscores Zynext Ventures’ commitment to supporting disruptive healthcare innovations that address significant unmet medical needs. Illexcor is developing